May 2022 "We are thrilled to announce that our co-founder Margaux Duchamp has been selected as a 30 under 30 Europe Forbes ranking 2022 for science and healthcare. #ForbesUnder30 #ArcoScreen #sciences #EPFL" Read more at the source #DrGPCR #GPCR #IndustryNews

May 2022 "Seoul, South Korea, 28 April 2022 – GPCR therapeutics, Inc., a venture-backed clinical stage international biopharmaceutical company with an innovative approach to drug discovery based on targeting G Protein Coupled Receptors (GPCR) pairs, today announced four appointments to its Scientific Advisory Board (SAB). Dr. Michel Bouvier, Dr. Luisa Salter-Cid, Dr. Omar Nadeem and Dr. Jon Wigginton will provide scientific expertise to support the company’s research and clinical development. GPCR just had a very successful first meeting including all the Scientific Advisory Board." Read more at the source #DrGPCR #GPCR #IndustryNews

May 2022 "Published: May 10, 2022 To accelerate clinical development of its best-in-class and first-in-class immuno-oncology programs STRASBOURG, France & MONTREAL- Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology, announced today the closing of a US $42m (€39m) series A financing round co-led by Panacea Venture, CTI Life Sciences and 3B Future Health Fund, and joined by adMare BioInnovations, Schroders Capital, Omnes, Turenne Capital, Theodorus, Viva BioInnovator and existing investor Seventure Partners." Read more at the source #DrGPCR #GPCR #IndustryNews

April 2022 John Streicher talks about his work on terpenes found in cannabis as these may be a novel way to treat pain without the negative side effects "Many people are familiar with cannabis, but John Streicher, PhD, takes a closer look at the plant’s aromatic chemical compounds called terpenes. These compounds may be a novel way to treat pain without the negative side effects of cannabinoids or opioids." Read more at the source #DrGPCR #GPCR #IndustryNews

April 2022 "By Cliona MacSweeney | Apr 20, 2022 Cliona MacSweeney, a project director in our Translational Medicine department, recently presented this important pre-clinical work at SIRS2022 confirming the ability of the highly selective novel GPR52 agonist HTL00411718 to modulate centrally mediated locomotor activity in response to A2A receptor antagonists. This work highlights an important interplay between the adenosinergic and dopaminergic systems and suggests the potential for GPR52 agonists to control neuropsychiatric symptoms in conditions such as schizophrenia. " Read more at the source #DrGPCR #GPCR #IndustryNews

April 2022 Design Pharmaceuticals Closes $5 Million Pre-series A Round to Accelerate Commercialization of Ultrahigh Throughput Drug Discovery Platform "April 12, 2022 07:00 AM Eastern Daylight Time CAMBRIDGE, Mass.--Design Pharmaceuticals, a company redesigning small molecule drug discovery, today announced the closing of a pre-series A round of $5 million, including an investment of $3 million from Virtus Inspire Venture Partners. The proceeds will be used to further build the company’s discovery platform and operations. Design Pharmaceuticals’ platform is based on ultrahigh-throughput technologies that biomine drug-like molecules from natural sources, such as microbiota. These molecules are then evaluated at unprecedented speed and scale on hundreds of GPCR targets simultaneously." Read more at the source #DrGPCR #GPCR #IndustryNews

April 2022 "SAN DIEGO, April 12, 2022 — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today the pricing of an underwritten follow-on offering of 5,625,563 shares of its common stock at a price to the public of $22.22 per share. All of the shares to be sold in the offering are to be sold by Crinetics. The gross proceeds to Crinetics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $125.0 million. The offering is expected to close on or about April 18, 2022, subject to the satisfaction of customary closing conditions." Read more at the source #DrGPCR #GPCR #IndustryNews

April 2022 Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare Fund, an affiliate of CBC Group "CHESTERBROOK, Pa., March 31, 2022 -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that the Company entered into a royalty-based financing with an affiliate of R-Bridge Healthcare Fund (the R-Bridge Financing)." Read more at the source #DrGPCR #GPCR #IndustryNews

April 2022 Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million ex-US Royalty-Based Financing with R-Bridge Healthcare Fund "CHESTERBROOK, Pa., April 18, 2022 - Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced receipt of the first $15 million tranche from its royalty-based financing agreement with an affiliate of R-Bridge Healthcare Fund (the R-Bridge Financing)." Read more at the source #DrGPCR #GPCR #IndustryNews

April 2022 Sosei Heptares Confirms Senior Leadership Changes to Drive the Company Through the Next Stage of its Evolution "New team focused on expanding its GPCR-focused structure-based drug design platform and enhancing translational medicine capabilities • ‘Venture-like’ capital allocation approach to focus pipeline development through to Phase 1b/2a clinical proof of concept in patients, and optimize value generation • Mid-term global expansion plans include drug discovery technology investments, licensing late-stage products for Japan, and strategic acquisitions • Mr. Chris Cargill appointed as President and Chief Executive Officer • Dr. Matt Barnes appointed President of Heptares Therapeutics Ltd., and Head of UK R&D Tokyo, Japan and Cambridge, UK, 24 March 2022 – Sosei Group Corporation (“the Company”; TSE: 4565) today confirms that a series of Executive Management changes have been approved at the Company’s 32nd Shareholders’ Meeting today and are effective immediately (see biographies at the end)." Read more at the source #DrGPCR #GPCR #IndustryNews

April 2022 Applying Allosteric Modulator Pharmacology to Treat Dyskinesia and Other Movement Disorders with Tim Dyer Addex Therapeutics "Tim Dyer is the Co-Founder and CEO of Addex Therapeutics, which is focusing on the pharmacology known as allosteric modulation. This emerging class of small molecule drugs known as allosteric modulators is being explored for treating central nervous system and neurologic disorders, particularly movement disorders like dyskinesia associated with Parkinson's and dystonia. Addex did not invent allosteric modulation but is pioneering the screening technologies to find these difficult to locate molecules." Read more at the source #DrGPCR #GPCR #IndustryNews

April 2022 Read more at the source #DrGPCR #GPCR #IndustryNews

April 2022 Addex Expands Pipeline With Selective M4 Positive Allosteric Modulator Program For The Treatment Of Schizophrenia & Other Psychotic Disorders "New Series of Potent and Selective Compounds Identified Using Proprietary Allosteric Modulator Screening Platform Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 6, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that it has moved a selective and potent M4 muscarinic receptor positive allosteric modulator (PAM) program into lead optimization. M4 PAMs have the potential to treat schizophrenia and other types of debilitating neuropsychiatric disorders." Read more at the source #DrGPCR #GPCR #IndustryNews

April 2022 Addex Therapeutics Completes Patient Enrollment For Dipraglurant Blepharospasm Phase 2 Clinical Study "Geneva, Switzerland, April 13, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that patient enrollment has been completed in its Phase 2a clinical study evaluating dipraglurant as a potential treatment for blepharospasm, a type of dystonia characterized by involuntary contractions or spasms of the eyelid muscles. Dipraglurant selectively targets the metabotropic glutamate receptor subtype 5 (mGlu5) through allosteric modulation to downregulate the neurotransmission believed to cause blepharospasm." Read more at the source #DrGPCR #GPCR #IndustryNews

March 2022 Confo Therapeutics Doses First Subjects In Phase 1 Clinical Trial Of CFTX-1554 For The Treatment Of Neuropathic Pain "— Confo’s first drug candidate moves into clinical development — Ghent, Belgium – March 10, 2022 – Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that the first subjects have been dosed in the company’s Phase 1, first-in-human trial of their clinical candidate CFTX-1554, a novel inhibitor of the angiotensin II type 2 receptor (AT2R). CFTX-1554 is being developed as a non-opioid approach to the treatment of neuropathic pain, a debilitating condition caused by damage to the nerves outside of the brain and spinal cord, for which current treatment methods are often insufficiently effective and can lead to serious side effects and addiction. The Phase 1 study will assess the safety, tolerability and pharmacokinetics of CFTX-1554 in healthy subjects (NCT05260658). " Read more at the source #DrGPCR #GPCR #IndustryNews

March 2022 Inversago Pharma Announces Dosing of First Participant with Metabolic Syndrome in Phase 1B Clinical Trial "MONTREAL (CANADA) – March 15, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announced today the dosing of the first participant with metabolic syndrome in a Phase 1b clinical trial. This 28-day trial will test the pharmacokinetics and safety profile of Inversago’s lead molecule, INV-202, on a targeted population with metabolic syndrome. Topline results from 40 subjects are expected in the second half of the calendar year." Read more at the source #DrGPCR #GPCR #IndustryNews

March 2022 "Congratulations to Richard J. Law, our newly named Chief Business Officer. Richard is the architect behind nearly all of Exscientia's partnerships and collaborations across pharma and #biotech⁠ and is an advocate for the role of #AI in drug discovery." Read more at the source #DrGPCR #GPCR #IndustryNews

March 2022 "Explicyte grants Domain Therapeutics exclusivity on data related to GPCR implicated in immunoresistance, to develop first-in class innovative cancer therapies. Strasbourg and Bordeaux, France, March 10, 2022 – Domain Therapeutics, a biopharmaceutical company specializing in the discovery and development of new drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), and Explicyte, an expert in the field of IO and innovative target identification through multiparametric approaches, announce today the signing of a partnership agreement. The two companies will combine their expertise to identify GPCR targets and associated biomarkers to discover and develop breakthrough therapeutic programs for IO. Financial terms are not disclosed." Read more at the source #DrGPCR #GPCR #IndustryNews

March 2022 Crinetics Pharmaceuticals Expands Executive Team With Appointment Of James Hassard As Chief Commercial Officer "SAN DIEGO – March 1, 2022 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the appointment of James Hassard as chief commercial officer. Mr. Hassard is a commercial leader with more than three decades of experience leading sales and marketing operations for both global and domestic biotechnology companies." Read more at the source #DrGPCR #GPCR #IndustryNews

Are you ready? Tomorrow is the day for another Dr. GPCR Virtual Cafe. This time with none other than Dr. Bryan Roth There are 10 open tickets available. Get yours now! https://www.ecosystem.drgpcr.com/dr-gpcr-virtual-cafe/ #gpcr #drgpcr #virtualcafe

Mark your calendars! The Dr. GPCR Podcast is back this week with a brand new episode. Our guest is none other than Dr. Juan Jose Fung, Principal Scientist, at GPCR Therapeutics. Stay tuned as the episode will be released later this week. Subscribe today! https://buff.ly/32fzGbO #gpcr #drgpcr #podcast

Next on the Dr. GPCR Podcast, we have none other than Dr. Marta Filizola! Subscribe to the podcast today and get notified when new episodes are released! You can also leave us a review on Apple Podcast! https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ #gpcr #drgpcr #podcast

Mark your calendars and get your ticket today! The Dr. GPCR Virtual Cafe is back! Our first guest speaker is none other than Dr. Ben Myers! Learn about communication between GPCRs and PKA, Class F GPCR Smoothened & the Hedgehog signaling pathway! https://www.ecosystem.drgpcr.com/dr-gpcr-virtual-cafe

Next on the Dr. GPCR Podcast, we have Dr. Pina Cardarelli, CSO of GPCR Therapeutics. Subscribe to the podcast today and get notified when new episodes are released! ecosystem.drgpcr.com/dr-gpcr-podcast/ #gpcr#drgpcr #podcast

February 2022 "We are proud to announce the success of our IPO! Thank you to our shareholders, both historical and new, for their trust. The €25 million fundraising gives us the means to achieve our ambitions: to become a leading player in the field of brain diseases! #IPO #biotech #innovation #traitements #addiction #cannabis #Trisomie21 #Downsyndrome" Read more at the source #DrGPCR #GPCR #IndustryNews

February 2022 Trevena Announces Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu Nhwa Pharmaceutical "Submission supported by data from a Phase 3 bridging study of oliceridine injection compared to IV morphine, conducted in China by Nhwa Trevena is eligible to receive future success payments upon approval and commercialization milestones, as well as a 10% royalty on net sales in China CHESTERBROOK, Pa., Jan. 27, 2022 A biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that China’s National Medical Products Administration (NMPA) has accepted submission of a New Drug Application (NDA) for oliceridine injection. The NDA was submitted by Trevena’s partner, Jiangsu Nhwa Pharmaceutical, and follows completion by Nhwa of a Phase 3 bridging trial for OLINVYK (oliceridine) injection, a novel IV analgesic that has been approved in the United States by the Food and Drug Administration (FDA) for use in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate." Read more at the source #DrGPCR #GPCR #IndustryNews

February 2022 Read more at the source #DrGPCR #GPCR #IndustryNews

Integration and Spatial Organization of Signaling by G Protein-Coupled Receptor Homo- and Heterodimer Information flow from a source to a receiver becomes informative when the recipient can process the signal into a meaningful form. Information exchange and interpretation is essential in biology and understanding how cells integrate signals from a variety of information-coding molecules into complex orchestrated responses is a major challenge for modern cell biology. In complex organisms, cell to cell communication occurs mostly through neurotransmitters and hormones, and receptors are responsible for signal recognition at the membrane level and information transduction inside the cell. The G protein-coupled receptors (GPCRs) are the largest family of membrane receptors, with nearly 800 genes coding for these proteins. The recognition that GPCRs may physically interact with each other has led to the hypothesis that their dimeric state can provide the framework for temporal coincidence in signaling pathways. Furthermore, the formation of GPCRs higher order oligomers provides the structural basis for organizing distinct cell compartments along the plasma membrane where confined increases in second messengers may be perceived and discriminated. Here, we summarize evidence that supports these conjectures, fostering new ideas about the physiological role played by receptor homo- and hetero-oligomerization in cell biology. Read full article

Episode 55 of the Dr. GPCR podcast is now available! Our guest is Mark Schmeizl! He is a pro at Matchmaking the top talent in the life sciences with the industry’s leading companies. Listen where you get your podcasts https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ #drgpcr #gpcr #podcast

January 2022 "We are an experienced, innovative, global team on a bold mission to improve health by creating and developing life-changing medicines for people around the world." Read more at the source #DrGPCR #GPCR #IndustryNews